STAT Plus: Something Ventured: Akrevia Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here.
Early-stage biotech companies are almost always raising money. That cash, CEOs say, fuels their amazing science and potentially amazing drugs.
Continue to STAT Plus to read the full story…
